Heparin-associated thrombocytopenia treatment with low molecular weight heparin.

Thrombosis and haemostasis ·Vol. 55 ·No. 1 ·1986-02-28 ·Pages 37-9

Vitoux JF, Mathieu JF, Roncato M, Fiessinger JN, Aiach M

Abstract

Eight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.

MeSH Terms

Aged Blood Platelets/immunology Female Heparin/adverse effects,therapeutic use Humans Immunoglobulin G/metabolism Male Middle Aged Platelet Count Thrombocytopenia/chemically induced,complications,drug therapy Thrombosis/complications,drug therapy

Chemicals

Immunoglobulin G Heparin

Authors & Affiliations

5 authors, click to expand affiliations / ORCID

Vitoux J F

Mathieu J F

Roncato M

Fiessinger J N

Aiach M

Article Info

Journal

Thrombosis and haemostasis

Abbr.

Thromb Haemost

ISSN

0340-6245

Published

1986-02-28

Pages

37-9

Language

English

Region

Germany

NLM ID

7608063

Subset

External Links

PubMed source View journal details

Analysis Services

Heparin-associated thrombocytopenia treatment with low molecular weight heparin.

Contact

WeChat Official Account